In this comprehensive review of the use of recombinant activated factor VII in nonhemophiliac patients who underwent cardiac surgery during the period 2003 through 2006 in Canada (nϭ503), we found that recombinant activated factor VII was used primarily when standard interventions had failed to control blood loss. Moreover, as far as could be determined within the confines of this observational study, we found that recombinant activated factor VII was associated with a reduction in transfusion of blood products and, after adjustment for patients' underlying risk profile and red blood cell transfusion rate, did not appear to be associated with increased or decreased mortality or major morbidity. Finally, our data also suggested that the effectiveness of the drug may be enhanced if it is given early in the course of refractory blood loss in the setting of adequate amounts of circulating coagulation factors. Adequately powered randomized clinical trials are needed to verify these findings. See p 331.
␣-Linolenic Acid and Risk of Nonfatal Acute Myocardial Infarction
Long-chain n-3 fatty acids from fish, eicosapentaenoic acid and docosahexaenoic acid, reduce cardiovascular mortality, but availability of fish is limited and probably insufficient to meet worldwide needs. ␣-Linolenic acid, an essential n-3 fatty acid found in vegetable cooking oils such as soybean and canola oils and other products of plant origin could be a viable alternative to fish oils. We determined whether ␣-linolenic acid was associated with risk of nonfatal acute myocardial infarction in 1819 case-control pairs from a population-based study in Costa Rica. Increased dietary ␣-linolenic acid assessed by questionnaire and in adipose tissue was associated with 39% and 59% lower risk of myocardial infarction, respectively. The relationship between ␣-linolenic acid and myocardial infarction was nonlinear, and it was evident only at low intake levels. Risk of myocardial infarction decreased by 57% when median intakes of 1.79 g/d (0.65% energy) were compared with 1.11 g/d (0.42% energy), but it did not decrease further with intakes Ͼ1.79 g/d. The amount of ␣-linolenic acid associated with risk reduction was small, and it could be obtained with 2 teaspoons of soybean or canola oils, which are common plant sources of ␣-linolenic acid. This level of intake also could be easily achieved with intake of flaxseed oil (Ϸ1 to 2 mL) or walnuts (Ϸ6 to 10 halves). Fish or eicosapentaenoic acid and docosahexaenoic acid intake at the levels found in this population did not modify the observed association. In summary, consumption of vegetable oils rich in ␣-linolenic acid could confer important cardiovascular protection. See p 339.
Aerobic Interval Training Versus Continuous Moderate Exercise as a Treatment for the Metabolic Syndrome: A Pilot Study
In recent years, consensus has been growing that physical inactivity accelerates the development of metabolic syndrome and that the level of aerobic fitness predicts survival in a metabolic syndrome population even when other traditional risk factors are present. However, the level and format of exercise that may yield optimal health benefits remain in dispute. In the present study, we sought to determine whether exercise intensity is critical in improving aerobic fitness and endothelial function and in reducing the degree of the metabolic syndrome and cardiovascular risk factors in patients with established metabolic syndrome. Patients Ϸ40 to 60 years of age of both sexes either were subjected to high-intensity aerobic interval training or moderate continuous exercise or received standard advice on physical activity. The protocols were made isocaloric so that only exercise intensity differed between the 2 intervention groups. This study demonstrates that high-intensity training relative to the individual's aerobic fitness level is feasible even in overweight patients with the metabolic syndrome who have several cardiovascular risk factors. It also shows that the intensity of exercise is important for reversing factors relating to the metabolic syndrome, improving aerobic capacity, and improving endothelial function in patients with metabolic syndrome. Although the safety of high-intensity exercise has yet to be assessed, these results suggest that exercise intensity should be seriously considered by healthcare professionals and policy makers. See p 346.
Alternative Splicing of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Is Associated With Plasma Low-Density Lipoprotein Cholesterol Response to Simvastatin
Statins reduce low-density lipoprotein cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), a rate-limiting enzyme for cholesterol synthesis. Although statins are generally efficacious, a wide range of low-density lipoprotein cholesterol-lowering response exists among individuals. We have identified an alternatively spliced transcript of HMGCR that lacks exon 13, HMGCRv_1, and measured its expression in 170 simvastatinincubated immortalized lymphocyte cell lines derived from participants in the Cholesterol and Pharmacogenetics (CAP) study who were treated with simvastatin 40 mg/d for 6 weeks. We found that greater upregulation of HMGCRv_1 in vitro was significantly correlated (PՅ0.0001) with smaller in vivo reductions of plasma total and low-density lipoprotein cholesterol, triglycerides, and apolipoprotein B and explained 6% to 15% of the variation in the statin response of these measurements. Artificial enrichment of HMGCRv_1 via siRNA produced cells relatively resistant to statin inhibition, consistent with the association of increased alternative splicing with reduced statin response in the CAP study. Our findings point to a major role of HMGCR alternative splicing in influencing cholesterol response to statin treatment and exemplify how alternative splicing can act as a modifier of drug response. Although measurement of HMGCRv_1 expression on its own does not yet have clinical utility, its importance lies in highlighting new pathways and effects mediated by alternative splicing and its impacts on mechanisms related to cholesterol metabolism. This information also may lead to improved prediction of individuals who would be most likely to benefit from statin treatment and to the identification of new drug targets for improving statin efficacy. See p 355.
Mast Cells Play a Critical Role in the Pathogenesis of Viral Myocarditis
Mast cells are multifunctional cells that contain various mediators such as cytokines, histamine, proteases, and leukotrienes. They are found in nearly all major organs of the body and are involved in many types of inflammation as well as allergic inflammation.
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Original Research Put Into Perspective for the Practicing Clinician Recently, we showed that the gene expressions of the mast cells chymase and tryptase were increased in the acute stages of heart failure and viral myocarditis, suggesting that viral infection may also activate mast cells. In the present study, survival of mice was better in mast cell-deficient mice infected with encephalomyocarditis virus and in association with less-pronounced myocardial necrosis, inflammation, and gene expressions of proinflammatory cytokines. Of note, all of these reactions were restored in mast cell-reconstituted mice. A histamine H1-receptor antagonist also alleviated viral myocarditis. These observations suggest that mast cells participate in the acute inflammatory reaction and the onset of ventricular remodeling associated with acute viral myocarditis and that the inhibition of their function may be therapeutic in this disease. See p 363.
Mechanisms of Preejection and Postejection Velocity Spikes in Left Ventricular Myocardium: Interaction Between Wall Deformation and Valve Events
Tissue Doppler echocardiography is used clinically to assess left ventricular systolic and diastolic function in terms of myocardial velocities during ejection and filling, respectively. In addition, brief velocity spikes occur before and after ejection, but the cause and clinical importance of these velocity spikes have been debated. This combined experimental and clinical study indicates that the normal preejection velocity spike is due to myocardial shortening, which displaces blood toward the mitral region and causes bulging of the mitral leaflets into the left atrium; when the valve reaches its final closing position, preejection shortening is suddenly arrested. Hence, the initial shortening is reflected by the upstroke of the spike, whereas the downstroke reflects the interrupted shortening. The postejection velocity spike appears to be caused by a similar mechanism; reverse blood flow closes the aortic valve and slightly expands the ventricle until valve closure interrupts the expansion. The expansion is seen as a negative velocity at end systole, and the interruption of lengthening is reflected by the upstroke of the postejection velocity spike. In the normal heart, onset of shortening occurs simultaneously throughout the left ventricular wall as indicated by synchronous preejection velocity spikes in different left ventricular wall regions. Thus, investigation of preejection wall deformation may allow assessment of dyssynchronous contraction and the effects of resynchronization therapy. Furthermore, because preejection and postejection velocity spikes reflect valve events, they may represent a means to detect timing of valve closure and opening. See p 373.
Randomized, Controlled Trial of Coronary Artery Bypass Surgery Versus Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease: Six-Year Follow-Up From the Stent or Surgery Trial (SoS)
A number of randomized trials have compared revascularization by percutaneous coronary intervention or coronary artery bypass grafting (CABG) in the management of coronary artery disease, but only the more recent studies have involved the routine use of coronary stents. The Stent or Surgery (SoS) trial is an international multicenter trial that randomized patients with multivessel coronary artery disease to revascularization with CABG or percutaneous coronary intervention with bare-metal stent technology. A total of 988 patients (nϭ488 percutaneous coronary intervention, nϭ500 CABG) were randomized at 53 centers during the period from 1996 to 1999. The aim of the present study is to report long-term survival in the SoS trial. Investigators established survival status from hospital or community medical records or national databases or by direct contact with patients and their relatives. At a median follow-up of 6 years, 53 patients (10.9%) died in the percutaneous coronary intervention group compared with 34 (6.8%) in the CABG group (hazard ratio 1.66, 95% confidence interval 1.08 to 2.55, Pϭ0.022). Little evidence was found that the treatment effect on mortality differed between subgroups according to baseline angina grade (interaction test Pϭ0.52), the severity of coronary disease (Pϭ0.92), or diabetic status (Pϭ0.15). At a median follow-up of 6 years, a continuing survival advantage was observed for patients managed with CABG, although this is not consistent with results from other stent-versus-CABG studies. See p 381.
Improved Survival After Out-of-Hospital Cardiac Arrest Is Associated With an Increase in Proportion of Emergency Crew-Witnessed Cases and Bystander Cardiopulmonary Resuscitation
Out-of-hospital cardiac arrest (OHCA) is a leading cause of death in the Western world and accounts for Ͼ50% of deaths due to adult coronary heart disease. Despite considerable efforts to improve the various links in the chain of survival, OHCA remains associated with a poor prognosis. The aim of this study was to explore the temporal trends of survival after OHCA with regard to factors mainly related to the prehospital phase and resuscitation. We examined all patients experiencing OHCA in whom cardiopulmonary resuscitation (CPR) was attempted between 1992 and 2005 in Sweden (nϭ38 646). The proportion surviving for 1 month after arrest increased significantly from 4.8% in 1992 to 7.3% in 2005. The increase in survival was particularly marked among patients found with a shockable rhythm and was associated with an increase in the proportion of emergency medical crew-witnessed arrests and, to a lesser degree, an increase in the performance of bystander CPR. These findings suggest that many lives could be saved if patients with cardiac symptoms such as chest pain received more rapid assessment from emergency medical teams. Two principal methods can be used to achieve this result: earlier placement of calls to emergency dispatch centers and shorter time intervals from OHCA to treatment (ie, CPR and defibrillation). Education of patients, their families, and the public may well be ways to reach the first group, whereas increased use of CPR, public access defibrillation, and early first-responder defibrillation are methods to reach the latter. See p 389.
